Prognostic significance of colony-stimulating factor receptor expression in ipsilateral breast cancer recurrence.
The macrophage colony-stimulating factor receptor (CSF-1R), the product of the c-fms proto-oncogene, regulates normal proliferation and differentiation of macrophages and trophoblasts. Recent research found abnormal expression of CSF-1R in human carcinomas of the breast, endometrium, and ovary. Furthermore, activation of CSF-1R by its ligand has been shown to regulate invasiveness and anchorage-independent growth in breast carcinoma cells. To study the significance of CSF-1R expression in breast cancer, we designed a case-controlled immunohistochemical study. We chose 80 patients from a database of 1200 early stage I or II breast cancer patients treated with conservative surgery and radiation therapy. Expression of CSF-1R in the tumors of 40 patients who experienced an ipsilateral breast tumor recurrence (IBTR) as a primary site of relapse were compared with 40 patients who had not experienced an IBTR. The index and control patients were matched by age, clinical stage, nodal status, and follow-up. Paraffin-embedded sections were immunostained with antibodies directed toward CSF-1R. For the CSF-1R antibody, a total of 28 index cases (70%) demonstrated strong staining, whereas only 16 control cases (40%) demonstrated high immunoreactivity (P = 0.007). The CSF-1R antibody showed a positive correlation for local relapse, but no correlation was found between CSF-1R expression and distant metastasis. In summary, our findings provide evidence for the poor prognostic role of CSF-1R in IBTR.
Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut 06520-8040, USA.
M G
MG
Maher
E
E
Sapi
B
B
Turner
A
A
Gumbs
P L
PL
Perrotta
D
D
Carter
B M
BM
Kacinski
B G
BG
Haffty
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000473:pathology / Q000648:ultrastructure*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000648:ultrastructure*; D009367:Neoplasm Staging; D011379:Prognosis; D000090063:Proto-Oncogene Mas; D016184:Receptors, Colony-Stimulating Factor / Q000096:biosynthesis*; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D013194:Staining and Labeling
C000715470:MAS1 protein, human; D000090063:Proto-Oncogene Mas; D016184:Receptors, Colony-Stimulating Factor; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone